Liu Fang, Fan Dongmei, Qi Jing, Zhu Huifang, Zhou Yuan, Yang Chunzheng, Zhu Zhenping, Xiong Dongsheng
State Key Laboratory of Experimental Hematology, Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, PR China.
Life Sci. 2008 Sep 26;83(13-14):496-501. doi: 10.1016/j.lfs.2008.07.017. Epub 2008 Aug 3.
The aim was to determine whether increased CK8 and BCRP expression cooperatively contribute to multidrug resistance (MDR) in MCF-7/MX cells. Accumulating evidence suggests that the development and maintenance of cancer MDR involves complex multimodal mechanisms that interact concomitantly and complementarily. In this report, we observed elevated expression of cytokeratin 8 (CK8) in MCF-7/MX, a mitoxantrone (MX)-selected human breast tumor cell line with the MDR phenotype known as overexpression of breast cancer resistant protein (BCRP).
Gene transfection methods were used to express CK8 and BCRP in NIH3T3 fibroblasts, individually or in combination.
Taken together, our present study suggests that CK8 together with BCRP may play significant roles in conferring the multifactorial MDR phenotype of MCF-7/MX cells, but may act independently via potentially different mechanisms. Although expressing either CK8 or BCRP alone was able to confer resistance to mitoxantrone, cells co-expressing both proteins demonstrated significantly increased drug resistance. Furthermore, RNAi knockdown of CK8 and BCRP, alone and in combination, in MCF-7/MX cells significantly attenuated their resistance to chemotherapeutic agents. Interestingly, in contrast to inhibition of BCRP expression via anti-BCRP shRNA vector transfection, reversal of mitoxantrone resistance by transfection with anti-CK8 shRNA was not accompanied by an increase in intracellular drug accumulation.
Combinational approaches that target multiple drug-resistance-related molecules/pathways in cancer cells may represent more efficacious strategies to overcome MDR.
本研究旨在确定细胞角蛋白8(CK8)表达增加与乳腺癌耐药蛋白(BCRP)是否共同导致MCF-7/MX细胞的多药耐药(MDR)。越来越多的证据表明,癌症多药耐药的发生和维持涉及复杂的多模式机制,这些机制相互作用并相互补充。在本报告中,我们观察到在MCF-7/MX细胞中细胞角蛋白8(CK8)表达升高,MCF-7/MX是一种经米托蒽醌(MX)筛选的具有多药耐药表型的人乳腺肿瘤细胞系,其特征为乳腺癌耐药蛋白(BCRP)过表达。
采用基因转染方法分别或联合在NIH3T3成纤维细胞中表达CK8和BCRP。
综合来看,我们目前的研究表明,CK8与BCRP可能在赋予MCF-7/MX细胞多因素多药耐药表型中发挥重要作用,但可能通过潜在的不同机制独立发挥作用。虽然单独表达CK8或BCRP都能赋予对米托蒽醌的耐药性,但同时表达这两种蛋白的细胞显示出显著增强的耐药性。此外,在MCF-7/MX细胞中单独或联合敲低CK8和BCRP的RNA干扰显著减弱了它们对化疗药物的耐药性。有趣的是,与通过抗BCRP shRNA载体转染抑制BCRP表达不同,用抗CK8 shRNA转染逆转米托蒽醌耐药性并未伴随细胞内药物积累增加。
针对癌细胞中多种耐药相关分子/途径的联合方法可能是克服多药耐药更有效的策略。